Role of EMT (epithelial mesenchymal transition) in metastatic breast cancer: Association with eribulin and cyclin dependent kinase inhibitor treatment and disease recurrence

Breast Cancer Research Centre - WA0 个研究点目标入组 252 人开始时间: 2021年2月25日最近更新: 2022年3月7日

适应症

试验速览

暂无简介。

•a) Consent to use of tumour tissue
•b) Histologically confirmed BC with archived primary BC tissue available
•c) Diagnosis of metastatic BC where histological confirmation has been
•confirmed in patient with de novo metastatic BC or histological/ cytological /
•unequivocal radiologic diagnosis of metastatic disease in a patient with prior
•diagnosis breast cancer
•d) Patients with hormone receptor positive, HER2 negative BC who have (i)
•received a cyclin D kinase inhibitor in the adjuvant setting and who has
•experienced a BC recurrent event or (ii) received a cyclin D kinase inhibitor in
•the metastatic setting
•e) Any metastatic BC patient who has received at least one dose of eribulin in
•the course of their metastatic BC

•a) Non-breast metastatic malignancy after BC diagnosis
•b) Lost to follow-up (incomplete data in medical records and/or PI's secure database to provide adequate information)
•c) Inadequate tumour tissue for biomarker analysis

发起方

Breast Cancer Research Centre - WA